Precision probiotics for hair loss treatment through gut-skin axis
Bioithas presents a precision probiotic solution targeting hair loss associated with alopecia areata and androgenetic alopecia. Preliminary studies show promising results in scalp condition improvement, with ongoing trials to validate effectiveness across different alopecia types.
Overview
Bioithas is developing a precision probiotic solution aimed at addressing hair loss conditions, specifically alopecia areata and androgenetic alopecia. The probiotics are designed to influence the gut-skin axis, potentially modifying the microbiota to positively impact hair follicle health. Preliminary clinical studies have shown promising results, with a higher response rate in patients treated with probiotics compared to placebo groups.
Technical specifications
- Target Conditions: Alopecia areata, androgenetic alopecia, and frontal fibrosing alopecia.
- Mechanism: Modulation of gut microbiota to influence immune responses associated with hair follicle health.
- Clinical Study Results: Initial pilot studies indicate improved disease activity and regrowth in probiotic-treated groups.
- Future Trials: Plans are underway for expanded clinical trials with larger patient cohorts and additional studies on related alopecia types.
Technology readiness level
The technology is currently at TRL 7, having been validated in a clinical setting with ongoing plans for further trials to establish broader efficacy across multiple alopecia conditions.
About BIOITHAS
Bioithas is a Spanish biotechnology and pharmaceutical company that develops clinically-formulated probiotic supplements, biomarkers, and diagnostic tools. Founded in 2017 and based in Alicante, the firm operates as a research center that studies the human microbiota and its connection to various pathologies. By leveraging scientific research and conducting clinical trials, Bioithas creates innovative probiotic blends designed for skin, digestive, and immune health. The company also serves as a contract research organization (CRO), offering scientific consulting and patent licensing services to other pharmaceutical and industrial partners.
The company's work is essential for customers and partners seeking scientifically-validated, probiotic-based adjuvant treatments for conditions such as atopic dermatitis, psoriasis, and acne. By adhering to the rigorous methodology of clinical trials, Bioithas ensures its products meet objective effectiveness standards. Through its focus on the human microbiome as a therapeutic target, the company bridges the gap between scientific investigation and consumer health, providing patent-backed products that complement natural biological processes. Their research efforts include exploring links between microbiota and diseases like multiple sclerosis and various cancers, establishing them as a key player in clinical-grade microbiome research.
delivered to your inbox.